Related Experiment Videos
The antiarrhythmic potential of angiotensin II antagonism: experience with losartan
1Department of Medicine, Boston University School of Medicine, Massachusetts 02118, USA.
Insights
Inhibition of the renin-angiotensin system, particularly with angiotensin II receptor blockers like losartan, offers significant protection against heart disease and arrhythmias. This approach reduces mortality and sudden cardiac death in patients with heart failure.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Renin-angiotensin system (RAS) inhibition is established for protecting organs from hypertension.
- Angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in ischemic heart disease and heart failure.
- ACE inhibitors may decrease sudden deaths by reducing complex arrhythmias.
Purpose of the Study:
- To review the arrhythmogenic properties of angiotensin II.
- To explore the antiarrhythmic potential of losartan, an angiotensin II type 1 receptor antagonist.
- To discuss the pharmacologic mechanisms underlying losartan's antiarrhythmic effects.
Main Methods:
- Literature review of studies on RAS inhibition and cardiovascular outcomes.
- Analysis of clinical trial data comparing ACE inhibitors and angiotensin II receptor antagonists.
- Examination of preclinical and clinical evidence on angiotensin II's role in cardiac arrhythmias.
Main Results:
- Losartan demonstrated a 46% mortality reduction compared to captopril in elderly heart failure patients.
- Evidence suggests angiotensin II contributes to cardiac arrhythmogenesis.
- Losartan exhibits antiarrhythmic properties, potentially through blocking angiotensin II type 1 receptors.
Conclusions:
- Inhibition of the renin-angiotensin system, including with angiotensin II receptor antagonists like losartan, is crucial for managing hypertensive complications.
- Losartan shows promise in reducing mortality and potentially preventing sudden cardiac death in heart failure patients.
- Understanding the mechanisms of angiotensin II's arrhythmogenic effects can guide the development of novel antiarrhythmic therapies.
Abstract:
A large body of literature accumulated over the past several years supports the notion that inhibition of the renin-angiotensin system protects the heart and other target organs from hypertensive complications. Various studies have shown that angiotensin-converting enzyme inhibitors reduce morbidity and mortality in the setting of ischemic heart disease and/or congestive heart failure. The improvement in survival has been attributed in part to a significant decrease in the incidence of sudden deaths, possibly due to a decrease in complex arrhythmia episodes. Recently, the angiotensin II type 1 receptor antagonist losartan was shown to reduce mortality by 46% compared with captopril in older patients with chronic congestive heart failure. This paper briefly reviews the arrhythmogenic properties of angiotensin II and the possible pharmacologic mechanisms for the antiarrhythmogenic potential of losartan.